May 3, 2018
- FDA D.I.S.C.O.: A new drug approval for non-metastatic castration-resistant prostate cancer - Transcript
- FDA D.I.S.C.O.: A new drug approval for non-metastatic castration-resistant prostate cancer - mp3
- FDA's Clinical Data Summary Pilot Program: Questions Frequently Asked by Industry
- FDA Drug Shortages
- Bupivacaine Hydrochloride and Epinephrine Injection, USP (Updated - Currently in Shortage)
- Bupivacaine Hydrochloride Injection, USP (Updated - Currently in Shortage)
- Calcium Gluconate Injection (Updated - Currently in Shortage)
- Cefotetan Disodium Injection (Updated - Currently in Shortage)
- Hydromorphone Hydrochloride Injection, USP (Updated - Currently in Shortage)
- Lidocaine Hydrochloride (Xylocaine) Injection (Updated - Currently in Shortage)
- Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine (Updated - Currently in Shortage)
- Lorazepam Injection, USP (New - Currently in Shortage)
- Potassium Chloride Injection (Updated - Currently in Shortage)
- Ropivacaine Hydrochloride injection (Updated - Currently in Shortage)
- Sodium Chloride 0.9% Injection Bags (Updated - Currently in Shortage)
- Sodium Iodide I 131 Capsules (New - Discontinuation)
- Sodium Iodide I 131 Solution (New - Discontinuation)
- Sterile Water (Updated - Currently in Shortage)
- La FDA advierte sobre una reacción grave del sistema inmunitario con el medicamento para convulsiones y enfermedades psiquiátricas lamotrigina (Lamictal)
- Approval and Reports (updated)
.png)
No hay comentarios:
Publicar un comentario